Here are the 10-K annual reports from Calidi Biotherapeutics, Inc. (CLDI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CLDI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDI filings page.
Calidi Biotherapeutics, Inc. filed its annual report for the year ended December 31, 2025, outlining a high-risk biotech profile focused on oncolytic virus cancer therapies. The company has no approved products, has not generated revenue from product sales, and has incurred significant operating losses.
Management discloses it has insufficient cash to continue operations for the next 12 months, creating substantial doubt about its ability to continue as a going concern and a need for substantial additional funding. Calidi’s lead RedTail candidate, CLD-401, is planned for a first-in-human Phase 1 trial by the end of 2026, while CLD-201 (SuperNova) has an approved IND and FDA Fast Track Designation for soft tissue sarcoma, and CLD-101 (NeuroNova) is in early-stage glioma trials run by academic partners.